(CLX) The Clorox - Overview
Stock: Bleach, Disinfectants, Litter, Dressings, Filters
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.08% |
| Yield on Cost 5y | 3.06% |
| Yield CAGR 5y | 2.03% |
| Payout Consistency | 89.4% |
| Payout Ratio | 75.3% |
| Risk 5d forecast | |
|---|---|
| Volatility | 22.6% |
| Relative Tail Risk | 0.66% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.83 |
| Alpha | -21.72 |
| Character TTM | |
|---|---|
| Beta | 0.238 |
| Beta Downside | 0.183 |
| Drawdowns 3y | |
|---|---|
| Max DD | 40.45% |
| CAGR/Max DD | -0.10 |
Description: CLX The Clorox January 03, 2026
The Clorox Company (NYSE:CLX) is a diversified consumer-goods firm that markets cleaning, hygiene, and home-care products worldwide through four operating segments: Health & Wellness, Household, Lifestyle, and International. Its flagship brands include Clorox, Pine-Sol, Glad, Kingsford, Brita, Burt’s Bees, and Hidden Valley, covering everything from bleach and disinfectants to cat litter, food-service dressings, and water-filtration systems.
In FY 2023 the company generated roughly $8.8 billion in revenue, delivering an adjusted operating margin of about 15 % and a free-cash-flow conversion rate near 70 %. CLX maintains a dividend yield of ~2.6 % and has returned over $2 billion to shareholders via buybacks and dividends in the past three years, reflecting its strong cash generation and commitment to capital allocation.
Key economic drivers for Clorox include persistent consumer demand for hygiene and cleaning products-accelerated by the COVID-19 pandemic-and the ability to pass through inflationary cost pressures, given its pricing power in the household-products sector, which is projected to grow at a modest 3 % CAGR through 2027. Additionally, sustainability trends are boosting sales of reusable water-filtration (Brita) and natural personal-care (Burt’s Bees) lines, providing incremental growth avenues.
For a deeper quantitative view of CLX’s valuation metrics, the ValueRay platform offers a concise dashboard.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 755.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA 1.40 > 1.0 |
| NWC/Revenue: -9.16% < 20% (prev -1.37%; Δ -7.79% < -1%) |
| CFO/TA 0.18 > 3% & CFO 984.0m > Net Income 755.0m |
| Net Debt (2.99b) to EBITDA (1.31b): 2.27 < 3 |
| Current Ratio: 0.74 > 1.5 & < 3 |
| Outstanding Shares: last quarter (121.9m) vs 12m ago -2.20% < -2% |
| Gross Margin: 44.04% > 18% (prev 0.44%; Δ 4359 % > 0.5%) |
| Asset Turnover: 120.8% > 50% (prev 128.5%; Δ -7.69% > 0%) |
| Interest Coverage Ratio: 10.30 > 6 (EBITDA TTM 1.31b / Interest Expense TTM 106.0m) |
Altman Z'' 0.73
| A: -0.11 (Total Current Assets 1.73b - Total Current Liabilities 2.35b) / Total Assets 5.61b |
| B: 0.03 (Retained Earnings 190.0m / Total Assets 5.61b) |
| C: 0.20 (EBIT TTM 1.09b / Avg Total Assets 5.59b) |
| D: 0.03 (Book Value of Equity 162.0m / Total Liabilities 5.58b) |
| Altman-Z'' Score: 0.73 = B |
Beneish M -2.97
| DSRI: 1.18 (Receivables 671.0m/603.0m, Revenue 6.76b/7.17b) |
| GMI: 1.01 (GM 44.04% / 44.42%) |
| AQI: 0.96 (AQ_t 0.40 / AQ_t-1 0.42) |
| SGI: 0.94 (Revenue 6.76b / 7.17b) |
| TATA: -0.04 (NI 755.0m - CFO 984.0m) / TA 5.61b) |
| Beneish M-Score: -2.97 (Cap -4..+1) = A |
What is the price of CLX shares?
Over the past week, the price has changed by +5.36%, over one month by +15.76%, over three months by +15.28% and over the past year by -15.55%.
Is CLX a buy, sell or hold?
- StrongBuy: 2
- Buy: 2
- Hold: 13
- Sell: 3
- StrongSell: 1
What are the forecasts/targets for the CLX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 120.5 | 0.9% |
| Analysts Target Price | 120.5 | 0.9% |
| ValueRay Target Price | 128.8 | 7.9% |
CLX Fundamental Data Overview February 08, 2026
P/E Forward = 19.4932
P/S = 2.1544
P/B = 46.5805
P/EG = 3.8253
Revenue TTM = 6.76b USD
EBIT TTM = 1.09b USD
EBITDA TTM = 1.31b USD
Long Term Debt = 2.49b USD (from longTermDebt, last quarter)
Short Term Debt = 390.0m USD (from shortTermDebt, last quarter)
Debt = 3.22b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.99b USD (from netDebt column, last quarter)
Enterprise Value = 17.55b USD (14.56b + Debt 3.22b - CCE 227.0m)
Interest Coverage Ratio = 10.30 (Ebit TTM 1.09b / Interest Expense TTM 106.0m)
EV/FCF = 22.56x (Enterprise Value 17.55b / FCF TTM 778.0m)
FCF Yield = 4.43% (FCF TTM 778.0m / Enterprise Value 17.55b)
FCF Margin = 11.51% (FCF TTM 778.0m / Revenue TTM 6.76b)
Net Margin = 11.17% (Net Income TTM 755.0m / Revenue TTM 6.76b)
Gross Margin = 44.04% ((Revenue TTM 6.76b - Cost of Revenue TTM 3.78b) / Revenue TTM)
Gross Margin QoQ = 43.16% (prev 41.57%)
Tobins Q-Ratio = 3.13 (Enterprise Value 17.55b / Total Assets 5.61b)
Interest Expense / Debt = 0.87% (Interest Expense 28.0m / Debt 3.22b)
Taxrate = 25.12% (54.0m / 215.0m)
NOPAT = 817.7m (EBIT 1.09b * (1 - 25.12%))
Current Ratio = 0.74 (Total Current Assets 1.73b / Total Current Liabilities 2.35b)
Debt / Equity = -25.74 (negative equity) (Debt 3.22b / totalStockholderEquity, last quarter -125.0m)
Debt / EBITDA = 2.27 (Net Debt 2.99b / EBITDA 1.31b)
Debt / FCF = 3.84 (Net Debt 2.99b / FCF TTM 778.0m)
Total Stockholder Equity = 50.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 13.49% (Net Income 755.0m / Total Assets 5.61b)
RoE = 1502 % (out of range, set to none) (Net Income TTM 755.0m / Total Stockholder Equity 50.2m)
RoCE = 43.06% (EBIT 1.09b / Capital Employed (Equity 50.2m + L.T.Debt 2.49b))
RoIC = 30.51% (NOPAT 817.7m / Invested Capital 2.68b)
WACC = 5.68% (E(14.56b)/V(17.78b) * Re(6.79%) + D(3.22b)/V(17.78b) * Rd(0.87%) * (1-Tc(0.25)))
Discount Rate = 6.79% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -1.09%
[DCF Debug] Terminal Value 86.88% ; FCFF base≈744.8m ; Y1≈788.4m ; Y5≈935.4m
Fair Price DCF = 204.6 (EV 27.73b - Net Debt 2.99b = Equity 24.74b / Shares 120.9m; r=5.90% [WACC]; 5y FCF grow 6.46% → 2.90% )
EPS Correlation: 32.79 | EPS CAGR: 1.59% | SUE: -0.11 | # QB: 0
Revenue Correlation: -24.05 | Revenue CAGR: -2.06% | SUE: 0.41 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.57 | Chg30d=+0.004 | Revisions Net=-2 | Analysts=14
EPS current Year (2026-06-30): EPS=5.92 | Chg30d=-0.064 | Revisions Net=-7 | Growth EPS=-23.3% | Growth Revenue=-8.4%
EPS next Year (2027-06-30): EPS=6.76 | Chg30d=+0.006 | Revisions Net=-3 | Growth EPS=+14.1% | Growth Revenue=+6.2%